Royalties in General. In consideration of the exclusive license granted to Licensee hereunder, Licensee shall pay or cause to be paid to Cellegy the Royalty set forth herein. The “Royalty” shall be equal to the following amounts:
Royalties in General. (a) In consideration of the exclusive worldwide license granted to ALGORX hereunder, ALGORX shall pay or cause to be paid to BRIDGE a running royalty based on Net Sales of all Licensed Products in all countries at a royalty rate as provided below: All payments due to BRIDGE that are not paid when due shall bear interest from the due date at the prime rate, as reported by The Wall Street Journal on the due date for such payment, plus ****** percent (**%) (or such lesser amount as may be the maximum permitted by law).
Royalties in General. In partial consideration for the license rights granted by QUALCOMM in Section 5.1, LICENSEE shall pay to QUALCOMM, no later than forty-five (45) days after the end of each calendar quarter, an amount equal to [***] ([***]) of the Net Selling Price of each OFDMA Smallcell that is Sold during such calendar quarter by LICENSEE or any of its Affiliates.
Royalties in General. For each Licensed Product, the obligation of VIA to pay Roche royalties based on sales of the Licensed Product in a given country shall commence on the date of the First Commercial Sale of such Licensed Product by the VIA Group in such country and shall continue until the later of (a) the date upon which there no longer exists in such country Roche Patent Rights having a Valid Claim that claims the manufacture, use or sale of such Licensed Product in such country, or (b) the date which is ten (10) years after the date of First Commercial Sale of such Licensed Product in such country. VIA shall pay or cause to be paid to Roche a royalty based on Net Sales made by the VIA Group in the Territory, on a country-by-country basis, at the applicable incremental royalty rate as provided for in the table below in this Section 4.1, subject to reduction as provided in Sections 4.3, 4.4, 4.5 and 4.6. Total, Territory-wide Annual Net Sales in a single calendar year Royalty Rate Amount of Net Sales up to and including $*** *** % Amount of Net Sales over $*** and up to and including $*** *** % Amount of Net Sales over $*** and up to and including $*** *** % Amount of Net Sales over $*** *** %
Royalties in General. For each Licensed Product, the obligation of VIA to pay Roche royalties based on sales of the Licensed Product in a given country shall commence on the date of the First Commercial Sale of such Licensed Product by the VIA Group in such country and shall continue until the later of (a) the date upon which there no longer exists in such country Roche Patent Rights having a Valid Claim that claims the manufacture, use or sale of such Licensed Product in such country, or (b) the date which is ten (10) years after the date of First Commercial Sale of such Licensed Product in such country. VIA shall pay or cause to be paid to Roche a royalty based on Net Sales made by the VIA Group in the Territory, on a country-by-country basis, at the royalty rate of *** percent (***%), subject to reduction as provided in Sections 4.3, 4.4, 4.5 and 4.6.
Royalties in General. Section 5.2.1.1 of the License Agreement is deleted in its entirety and replaced with the following:
Royalties in General. For each Licensed Product, the obligation of Licensee to pay Kosan royalties in a given country shall commence on the date of the First Commercial Sale of such Licensed Product by the Licensee in such country and shall continue until the later of (i) the date upon which no Valid Claim would cover the manufacture, use or sale of such Licensed Product in the country of manufacture, use or sale, or (ii) the date which is [*] after the date of such First Commercial Sale in such country (the “Royalty Term”).
Royalties in General. For each Licensed Product, the obligation of Miikana to pay Roche royalties based on sales of the Licensed Product in a given country shall commence on the date of the First Commercial Sale of such Licensed Product by the Miikana Group in such country and shall continue until the * of (a) the date upon which there no longer exists in such country a Patent within the Roche Patent Rights having a Valid Claim that claims the manufacture, use or sale of such Licensed Product in such country, or (b) subject to Section 4.3, the date which is * years after the date of First Commercial Sale of such Licensed Product in such country. Miikana shall pay or cause to be paid to Roche a royalty based on Net Sales made by the Miikana Group in the Territory, on a country-by-country basis, at the applicable incremental royalty rate as provided for in the table below in this Section 4.1, subject to reduction as provided in Section 4.3. Total, Territory wide Annual Net Sales in a single calendar year Royalty Rate Amount of Net Sales up to and including * * Amount of Net Sales over * and up to and including * * Amount of Net Sales over * and up to and including * * Amount of Net Sales over * *
Royalties in General. (a) In consideration of the exclusive license granted to GW hereunder, GW shall pay or cause to be paid to Cellegy a royalty equal the following:
Royalties in General. For each Licensed Product, the obligation of VIA to pay Roche royalties based on sales of the Licensed Product in a given country shall commence on the date of the First Commercial Sale of such Licensed Product by the VIA Group in such country and shall continue until the later of (a) the date upon which *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
